Melanoma mutations, either driver (BRAF, NRAS, NF1, GNAQ; identified in n = 29 patients) or other cancer-associated mutation (identified in n = 16 patients; defined in Table S5), were identified in 45/74 (61%) melanoma patients using our custom melanoma panel, 17/36 (47%) for stage III and 28/38 (74%) for stage IV (Figure 4A). This evidence concerns the gene NRAS and cancer.